Skip to main content
PMC home page
Journal of Clinical Pathology. Supplement (Royal College of Pathologists) logoLink to Journal of Clinical Pathology. Supplement (Royal College of Pathologists)
. 1975;9:106–114.

Hypolipaemic drugs and coronary heart disease

A N Howard 1
PMCID: PMC1347190  PMID: 783209

Full text

PDF
114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALTSCHUL R., HOFFER A., STEPHEN J. D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955 Feb;54(2):558–559. doi: 10.1016/0003-9861(55)90070-9. [DOI] [PubMed] [Google Scholar]
  2. BERGEN S. S., Jr, VAN ITALLIE T. B. Approaches to the treatment of hypercholesteremia. Ann Intern Med. 1963 Feb;58:355–366. doi: 10.7326/0003-4819-58-2-355. [DOI] [PubMed] [Google Scholar]
  3. Beaumont J. L., Carlson L. A., Cooper G. R., Fejfar Z., Fredrickson D. S., Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ. 1970;43(6):891–915. [PMC free article] [PubMed] [Google Scholar]
  4. Best M. M., Duncan C. H. Effects of clofibrate and dextrothyroxine singly and in combination on serum lipids. Arch Intern Med. 1966 Aug;118(2):97–102. [PubMed] [Google Scholar]
  5. Carlson L. A., Böttiger L. E. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet. 1972 Apr 22;1(7756):865–868. doi: 10.1016/s0140-6736(72)90738-6. [DOI] [PubMed] [Google Scholar]
  6. Carlson L. A., Orö L. Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis. 1973 Jul-Aug;18(1):1–9. doi: 10.1016/0021-9150(73)90113-5. [DOI] [PubMed] [Google Scholar]
  7. Christakis G., Rinzler S. H., Archer M., Winslow G., Jampel S., Stephenson J., Friedman G., Fein H., Kraus A., James G. The anti-coronary club. A dietary approach to the prevention of coronary heart disease--a seven-year report. Am J Public Health Nations Health. 1966 Feb;56(2):299–314. doi: 10.2105/ajph.56.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clifton-Bligh P., Miller N. E., Nestel P. J. Changes in plasma lipoprotein lipids in hypercholesterolaemic patients treated with the bile acid-sequestering resin, colestipol. Clin Sci Mol Med. 1974 Dec;47(6):547–557. doi: 10.1042/cs0470547. [DOI] [PubMed] [Google Scholar]
  9. Controlled trial of soya-bean oil in myocardial infarction. Lancet. 1968 Sep 28;2(7570):693–699. [PubMed] [Google Scholar]
  10. Dewar H. A., Oliver M. F. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. Br Med J. 1971 Dec 25;4(5790):784–786. doi: 10.1136/bmj.4.5790.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Evans R. J., Howard A. N., Hyams D. E. An effective treatment of hypercholesterolaemia using a combination of Secholex and clofibrate. Angiology. 1973 Jan;24(1):22–28. doi: 10.1177/000331977302400104. [DOI] [PubMed] [Google Scholar]
  12. Fredrickson D. S., Levy R. I., Lees R. S. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967 Feb 2;276(5):273–concl. doi: 10.1056/NEJM196702022760507. [DOI] [PubMed] [Google Scholar]
  13. Fredrickson D. S. Mutants, hyperlipoproteinaemia, and coronary artery disease. Br Med J. 1971 Apr 24;2(5755):187–192. doi: 10.1136/bmj.2.5755.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. GREENWOOD G. J. Neomycin ototoxicity; report of a case. AMA Arch Otolaryngol. 1959 Apr;69(4):390–397. doi: 10.1001/archotol.1959.00730030400002. [DOI] [PubMed] [Google Scholar]
  15. Gaut Z. N., Taylor W. J. Effects of large doses of nicotinyl alcohol on serum lipid levels and carbohydrate tolerance. J Clin Pharmacol J New Drugs. 1968 Nov-Dec;8(6):370–376. doi: 10.1002/j.1552-4604.1968.tb00112.x. [DOI] [PubMed] [Google Scholar]
  16. Gibson W. S., Jr Deafness due to orally administered neomycin. Arch Otolaryngol. 1967 Aug;86(2):163–165. doi: 10.1001/archotol.1967.00760050165008. [DOI] [PubMed] [Google Scholar]
  17. Greenberg L. H., Momary H. Audiotoxicity and nephrotoxicity due to orally administered neomycin. JAMA. 1965 Nov 15;194(7):827–828. [PubMed] [Google Scholar]
  18. Grundy S. M., Ahrens E. H., Jr, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 1971 Jul;78(1):94–121. [PubMed] [Google Scholar]
  19. Grundy S. M., Ahrens E. H., Jr, Salen G., Schreibman P. H., Nestel P. J. Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res. 1972 Jul;13(4):531–551. [PubMed] [Google Scholar]
  20. Grundy S. M., Ahrens E. H., Jr The effects of unsaturated dietary fats on absorption, excretion, synthesis, and distribution of cholesterol in man. J Clin Invest. 1970 Jun;49(6):1135–1152. doi: 10.1172/JCI106329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. HALPERN E. B., HELLER M. F. Ototoxicity of orally administered neomycin. Report of a case. Arch Otolaryngol. 1961 Jun;73:675–677. doi: 10.1001/archotol.1961.00740020689010. [DOI] [PubMed] [Google Scholar]
  22. Harthon L., Svedmyr N. Subacute administration of pentaerythritoltetranicotinate (Perycit) to man. Atherosclerosis. 1974 Jul-Aug;20(1):65–68. doi: 10.1016/0021-9150(74)90079-3. [DOI] [PubMed] [Google Scholar]
  23. Horning M. G., Hebert R. M., Roth R. J., Davis D. L., Horning E. C., Fischer E. P., Jordan G. L., Jr Effects of ethyl p-chlorophenoxyisobutyrate on biliary secretion of bile acids, cholesterol and phosphatidyl choline. Lipids. 1972 Feb;7(2):114–120. doi: 10.1007/BF02532598. [DOI] [PubMed] [Google Scholar]
  24. Howard A. N., Evans R. J. Secholex, Clofibrate and taurine in hyperlipidaemia. Atherosclerosis. 1974 Jul-Aug;20(1):105–116. doi: 10.1016/0021-9150(74)90084-7. [DOI] [PubMed] [Google Scholar]
  25. Howard A. N., Hyams D. E. Combined use of clofibrate and cholestyramine or DEAE sephadex in hypercholesterolaemia. Br Med J. 1971 Jul 3;3(5765):25–27. doi: 10.1136/bmj.3.5765.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. Br Med J. 1971 Dec 25;4(5790):775–784. [PMC free article] [PubMed] [Google Scholar]
  27. KING J. T. Severe deafness in an infant following oral administration of neomycin. J Med Assoc Ga. 1962 Nov;51:530–531. [PubMed] [Google Scholar]
  28. KUO P. T., BASSETT D. R. PRIMARY HYPERLIPIDEMIAS AND THEIR MANAGEMENT. Ann Intern Med. 1963 Oct;59:495–507. doi: 10.7326/0003-4819-59-4-495. [DOI] [PubMed] [Google Scholar]
  29. Krikler D. M., Lefevre D., Lewis B. Dextrothyroxine with propranolol in treatment of hypercholesterolaemia. Lancet. 1971 May 8;1(7706):934–936. doi: 10.1016/s0140-6736(71)91440-1. [DOI] [PubMed] [Google Scholar]
  30. Miller N. E., Clifton-Bligh P., Nestel P. J., Whyte H. M. Controlled clinical trial of a new bile acid-sequestering resin, colestipol, in the treatment of hypercholesterolaemia. Med J Aust. 1973 Jun 23;1(25):1223–1227. [PubMed] [Google Scholar]
  31. Miller N. E., Nestel P. J. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet. 1974 Oct 19;2(7886):929–931. doi: 10.1016/s0140-6736(74)91134-9. [DOI] [PubMed] [Google Scholar]
  32. Moutafis C. D., Myant N. B., Mancini M., Oriente P. Cholestyramine and nicotinic acid in the treatment of familial hyperbetalipoproteinaemia in the homozygous form. Atherosclerosis. 1971 Sep-Oct;14(2):247–258. doi: 10.1016/0021-9150(71)90054-2. [DOI] [PubMed] [Google Scholar]
  33. OLIVER M. F., BOYD G. S. Influence of reduction of serum lipids on prognosis of coronary heart-disease. A five-year study using oestrogen. Lancet. 1961 Sep 2;2(7201):499–505. doi: 10.1016/s0140-6736(61)92951-8. [DOI] [PubMed] [Google Scholar]
  34. OLIVER M. F., BOYD G. S. Reductuon of serum-cholesterol by dextro-thyroxine in men with coronary heart-disease. Lancet. 1961 Apr 15;1(7181):783–786. doi: 10.1016/s0140-6736(61)90115-5. [DOI] [PubMed] [Google Scholar]
  35. PARSONS W. B., Jr Treatment of hypercholesteremia by nicotinic acid. Progress report with review of studies regarding mechanism of action. Arch Intern Med. 1961 May;107:639–652. doi: 10.1001/archinte.1961.03620050005002. [DOI] [PubMed] [Google Scholar]
  36. STAMLER J., PICK R., KATZ L. N., PICK A., KAPLAN B. M., BERKSON D. M., CENTURY D. Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA. 1963 Feb 23;183:632–638. doi: 10.1001/jama.1963.03700080040013. [DOI] [PubMed] [Google Scholar]
  37. STARR P., ROEN P., FREIBRUN J. L., SCHLEISSNER L. A. Reduction of serum cholesterol by sodium dextro-thyroxine. Arch Intern Med. 1960 Jun;105:830–842. doi: 10.1001/archinte.1960.00270180008002. [DOI] [PubMed] [Google Scholar]
  38. Samuel P., Holtzman C. M., Goldstein J. Long-term reduction of serum cholesterol levels of patients with atherosclerosis by small doses of neomycin. Circulation. 1967 May;35(5):938–945. doi: 10.1161/01.cir.35.5.938. [DOI] [PubMed] [Google Scholar]
  39. Samuel P., Holtzman C. M., Meilman E., Sekowski I. Reduction of serum cholesterol and triglyceride levels by the combined administration of neomycin and clofibrate. Circulation. 1970 Jan;41(1):109–114. doi: 10.1161/01.cir.41.1.109. [DOI] [PubMed] [Google Scholar]
  40. Stone M. C., Thorp J. M., Mills G. L., Dick T. B. Diagnosis and classification of abnormal lipoprotein patterns. Clin Chim Acta. 1971 Feb;31(2):333–354. doi: 10.1016/0009-8981(71)90402-5. [DOI] [PubMed] [Google Scholar]
  41. Strisower E. H. The combined use of CPIB and thyroxine in treatment of hyperlipoproteinemias. Circulation. 1966 Feb;33(2):291–296. doi: 10.1161/01.cir.33.2.291. [DOI] [PubMed] [Google Scholar]
  42. Thompson G. R., Barrowman J., Gutierrez L., Dowling R. H. Action of neomycin on the intraluminal phase of lipid absorption. J Clin Invest. 1971 Feb;50(2):319–323. doi: 10.1172/JCI106497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. Br Med J. 1971 Dec 25;4(5790):767–775. [PMC free article] [PubMed] [Google Scholar]
  44. Turpeinen O., Miettinen M., Karvonen M. J., Roine P., Pekkarinen M., Lehtosuo E. J., Alivirta P. Dietary prevention of coronary heart disease: long-term experiment. I. Observations on male subjects. Am J Clin Nutr. 1968 Apr;21(4):255–276. doi: 10.1093/ajcn/21.4.255. [DOI] [PubMed] [Google Scholar]
  45. VAN ITALLIE T. B., HASHIM S. A. Clinical and experimental aspects of bile acid metabolism. Med Clin North Am. 1963 May;47:629–648. doi: 10.1016/s0025-7125(16)33569-6. [DOI] [PubMed] [Google Scholar]
  46. Weizel A., Estrich D. L., Splitter S. D., Pomeroy V., Kinsell L. W. Cholestyramine effect on plasma triglycerides in normolipidemic patients. Proc Soc Exp Biol Med. 1969 Jan;130(1):149–150. doi: 10.3181/00379727-130-33509. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology. Supplement (Royal College of Pathologists). are provided here courtesy of BMJ Publishing Group

RESOURCES